MedWatch

Novo Nordisk kicks off phase III trial program for new insulin hope

Even though the insulin market is under pressure, Novo Nordisk's faith in its new once-weekly insulin leads the firm to launch a major phase IIIa program for the drug

Photo: Mik Eskestad/ERH

Even though drugs like Ozempic and Rybelsus often steal the attention at Novo Nordisk, the firm is also highly occupied with its insulin business.

Most recently, Novo Nordisk launched the first trial in a large phase III program for the firm's new insulin icodec.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs